ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.
Several other equities research analysts have also recently weighed in on EPIX. Zacks Investment Research upgraded ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a report on Tuesday, January 16th. Bloom Burton upgraded ESSA Pharma from a “hold” rating to a “buy” rating in a report on Thursday, January 18th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $4.63.
Shares of ESSA Pharma (NASDAQ EPIX) opened at $0.20 on Friday. The firm has a market capitalization of $6.01, a PE ratio of -1.25 and a beta of 2.09. ESSA Pharma has a fifty-two week low of $0.15 and a fifty-two week high of $3.59. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of -1.32.
ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last issued its earnings results on Monday, December 11th. The company reported ($0.09) earnings per share for the quarter. equities analysts predict that ESSA Pharma will post -0.29 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This article was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/02/essa-pharma-epix-rating-increased-to-sell-at-valuengine.html.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.